Inactive Instrument

NTN Buzztime, Inc.

NTN

US6294106066

NTN Buzztime Inc. Announces Appointment of Kirk Nagamine as Chief Revenue Officer

April 16, 2013 at 02:13 pm EDT

NTN Buzztime Inc. announced the appointment of Kirk Nagamine as its new Chief Revenue Officer. In his new role, Mr. Nagamine will be responsible for the direction and management of the sales force and its operations and will drive the company's achievement of its customer acquisition and revenue goals. Mr. Nagamine joins Buzztime with over 20 years of executive management experience.

Prior to joining Buzztime, Mr. Nagamine has spent the last decade developing loyalty technologies used by small business and Fortune 500 companies alike. He brings a deep understanding of technology, business development and sales as well as significant experience in helping companies to monetize emerging technology based solutions. Mr. Nagamine's experience also includes serving as Senior Vice President of Sales for Fanfare Media Works Inc., Senior Vice President of Corporate Development for Entertainment Publications Inc. and Senior Vice President and General Manager of Sidewalk.com.

Latest news about NTN Buzztime, Inc.

EGames.com Holdings LLC completed the acquisition of Social entertainment, customer engagement, and advertising technology assets of NTN Buzztime, Inc..	21-03-25	CI
Brooklyn ImmunoTherapeutics LLC completed the acquisition of NTN Buzztime, Inc. in a reverse merger transaction.	21-03-24	CI
NTN Buzztime : Plans 1-for-2 Reverse Stock Split Prior to Merger; Shares Down 12% in Late Trading	21-03-23	MT
NTN Buzztime : Obtains Shareholder Approval for Brooklyn ImmunoTherapeutics Merger	21-03-16	MT
NTN Buzztime, Inc. has Changed its Name to Brooklyn ImmunoTherapeutics, Inc	21-03-15	CI
Ntn Buzztime, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-11	CI
NTN Buzztime : Earnings Flash (NTN) NTN BUZZTIME Reports Q3 Revenue $1.5M	20-11-13	MT
Ntn Buzztime, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-13	CI
EGames.com Holdings LLC entered into an asset purchase agreement to acquire Social entertainment, customer engagement, and advertising technology assets of NTN Buzztime, Inc. for $2 million.	20-09-17	CI
NTN Buzztime, Inc. announced that it expects to receive $1 million in funding from eGames.com Holdings LLC	20-09-12	CI
NTN Buzztime to Consider Options of Its Assets	20-08-14	CI
Brooklyn ImmunoTherapeutics LLC entered into the non-binding letter of intent to acquire NTN Buzztime, Inc. for approximately $170 million in a reverse merger transaction.	20-08-12	CI
Sean Gordon Provides Information to the Shareholders	20-06-05	CI
Transcript : NTN Buzztime, Inc., Q1 2020 Earnings Call, May 19, 2020	20-05-19
NTN Buzztime, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2020	20-05-19	CI
Ntn Buzztime, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-19	CI
NTN Buzztime, Inc. Announces Board Changes	20-04-03	CI
NTN Buzztime, Inc. Auditor Raises 'Going Concern' Doubt	20-03-18	CI
Transcript : NTN Buzztime, Inc., Q4 2019 Earnings Call, Mar 17, 2020	20-03-17
Ntn Buzztime, Inc. Reports Impairment Charges for the Fourth Quarter Ended on December 31, 2019	20-03-17	CI
NTN Buzztime, Inc. Appoints Allen Wolff as Chief Executive Officer and to Its Board of Directors	20-01-15	CI
Sporcle, Inc. entered into a definitive agreement to acquire Stump! Trivia business from NTN Buzztime, Inc. for $1.4 million.	20-01-13	CI
NTN Buzztime, Inc. Announces Board Changes	19-11-26	CI
NTN Buzztime, Inc. Announces Board Changes	19-11-26	CI
Transcript : NTN Buzztime, Inc., Q3 2019 Earnings Call, Oct 30, 2019	19-10-30

Chart NTN Buzztime, Inc.

Duration

Period

More charts

Company Profile

Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.

Sector

Broadcasting

More about the company

Sector Television Broadcasting

	1st Jan change	Capi.
WARNER BROS. DISCOVERY, INC.	-34.97%	18.13B
NEXSTAR MEDIA GROUP, INC.	+11.04%	5.71B
RTL GROUP S.A.	-14.47%	5.05B
NIPPON TELEVISION HOLDINGS, INC.	+60.21%	3.91B
SUN TV NETWORK LIMITED	+13.49%	3.81B
TEGNA INC.	-2.29%	2.54B
ZEE ENTERTAINMENT ENTERPRISES LIMITED	-43.39%	1.79B
M6 MÉTROPOLE TÉLÉVISION	-0.93%	1.76B
PT ELANG MAHKOTA TEKNOLOGI TBK	-26.44%	1.64B

Television Broadcasting